Pathogenic effector T cell (Tpeff)

Pathogenic effector T cells are a specialized subset of T lymphocytes that have lost self-tolerance and drive chronic inflammation and tissue damage in autoimmune and autoinflammatory diseases (Nature Reviews Immunology, 2020). Unlike regulatory T cells that maintain immune homeostasis, these cells—often characterized as Th1 or Th17 subsets—secrete high levels of pro-inflammatory cytokines such as interleukin-17 (IL-17), interferon-gamma (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Frontiers in Immunology, 2021). In conditions like multiple sclerosis, rheumatoid arthritis, and psoriasis, these cells infiltrate target organs and orchestrate a destructive immune response (PubMed, 2019). Therapeutic interventions targeting these cells range from monoclonal antibodies that block their entry into the central nervous system to small molecules that inhibit their signaling pathways or cytokine production (StatPearls, 2023). For example, drugs like natalizumab prevent these cells from crossing the blood-brain barrier, while secukinumab neutralizes the IL-17 they produce (FDA, 2020). Understanding the metabolic and transcriptional profile of these cells is a major focus of modern drug discovery to enable more selective immunosuppression without compromising overall host defense (Nature, 2022).

Other names

Pathogenic T cellEncephalitogenic T cellPro-inflammatory T cellEffector memory T cellTh17 cellTh1 cell

Mechanisms include the blockade of lymphocyte trafficking into tissues, inhibition of costimulatory signals required for activation, depletion of specific lymphocyte subsets, and neutralization of pro-inflammatory effector cytokines.